Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Papillomavirus Infections 40Uterine Cervical Neoplasms 22Uterine Cervical Dysplasia 5Virus Diseases 3Human Papillomavirus-Related Cervical Carcinoma 2Condylomata Acuminata 2Warts 1Precancerous Conditions 1Infections 1Human Papillomavirus Infection Leading to Cervical Cancer 1Hepatitis B 1Autoimmune Diseases 1Acquired Immunodeficiency Syndrome 1Abortion, Spontaneous 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 2adacel 1Tetanus Toxoid 1Human Papillomavirus Recombinant Vaccine nonavalent 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1Diphtheria-Tetanus-acellular Pertussis Vaccines 1Diphtheria Toxoid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Human Papillomavirus-Related Cervical Carcinoma × human papillomavirus vaccine, L1 type 16, 18 × Clear all
NCT05237947 2026-05-28

PRISMA

National Cancer Institute (NCI)

Phase 4 Active not recruiting
5,000 enrolled
Gynecologic

Human Papillomavirus-Related Cervical Carcinoma

NCT03728881 2025-08-03

PRIMAVERA

National Cancer Institute (NCI)

Phase 3 Completed
1,240 enrolled 107 charts
Gynecologic

Human Papillomavirus-Related Cervical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡